The effect of loss-of-function allele (CYP2C19*3) with Clopidogrel efficacy in coronary heart disease patients

Introduction: Clopidogrel is the most widely prescribed antiplatelet for patients with coronary heart disease (CHD) who cannot take aspirin. Despite its effectiveness, Clopidogrel has several side effects caused by its metabolite. Clopidogrel resistance has been identified in some patients, and patient factors such as genetic polymorphisms in CYP2C19 may play a role in this resistance. The researchers wanted to look at CYP2C19*3 polymorphisms and platelet aggregation in CHD patients who were taking clopidogrel. Methods: This research used a cross-sectional design. The research enrolled CHD patients at a local hospital's cardiology unit with certain inclusion and exclusion requirements. In the clinical laboratory, CYP2C19*3 polymorphisms was investigated using polymerase chain reaction (PCR), and platelet aggregation will be measured using light transmission aggregometry (LTA). Results: This research enlisted the participation of 53 patients. The majority of the patients (68%) were men, with the highest age group being 60-69 years old. The most common comorbid disorder was hypertension. The result of CYP2C19*3 polymorphisms as follows: GA (75%), AA (21%), and GG (4%). Hypo-aggregation (89%) and normal-aggregation (89%) are seen in the majority of patients (11%). The authors were unable to locate the patient who had hyper-aggregation. Conclusion: According to descriptive research, CYP2C19*3 polymorphisms caused hypo-aggregation in more patients than normal aggregation in this study.